Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 3
1964 1
1965 4
1966 3
1967 1
1968 2
1969 3
1970 2
1972 1
1973 2
1974 3
1975 1
1979 1
1980 2
1981 4
1982 2
1983 3
1984 1
1985 2
1986 3
1987 2
1988 3
1989 2
1990 1
1991 5
1992 8
1993 8
1994 7
1995 3
1996 5
1997 9
1998 11
1999 18
2000 26
2001 17
2002 20
2003 24
2004 29
2005 41
2006 51
2007 74
2008 98
2009 97
2010 102
2011 120
2012 118
2013 109
2014 131
2015 147
2016 154
2017 167
2018 156
2019 148
2020 151
2021 167
2022 172
2023 135
2024 147
2025 126
2026 75

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,612 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. van der Heijde D, et al. Among authors: song ih. Ann Rheum Dis. 2022 Nov;81(11):1515-1523. doi: 10.1136/ard-2022-222608. Epub 2022 Jul 4. Ann Rheum Dis. 2022. PMID: 35788492 Free PMC article. Clinical Trial.
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Blanco R, Duan Y, Li Y, Pangan AL, Wung P, Song IH. Deodhar A, et al. Among authors: song ih. Lancet. 2022 Jul 30;400(10349):369-379. doi: 10.1016/S0140-6736(22)01212-0. Lancet. 2022. PMID: 35908570 Clinical Trial.
Pharmacokinetics and Drug Interactions.
Choi MK, Song IS. Choi MK, et al. Among authors: song is. Pharmaceutics. 2026 Jan 4;18(1):67. doi: 10.3390/pharmaceutics18010067. Pharmaceutics. 2026. PMID: 41599173 Free PMC article.
Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells.
Lee S, Kim K, Jeong HJ, Choi S, Cheng H, Kim D, Heo S, Mun J, Kim M, Lee E, Choi YJ, Lee SG, Lee EA, Jang Y, Lim K, Kim HS, Jeong E, Myung SJ, Jung DB, Yu CS, Song IH, Corces MR, Kang JH, Myung K, Kwon T, Park TE, Joo J, Cho SW. Lee S, et al. Among authors: song ih. Cancer Res. 2025 Aug 1;85(15):2890-2904. doi: 10.1158/0008-5472.CAN-24-2938. Cancer Res. 2025. PMID: 40327605 Free PMC article.
Precise progerin targeting using RfxCas13d: A therapeutic avenue for Hutchinson-Gilford progeria syndrome.
Chae U, Yang HJ, Kim H, Lee SH, Lee DG, Koo JY, Ha SM, Bak SJ, Joo M, Nam HH, Lim KS, Kang P, Son HC, An YJ, Kim YH, Song IS, Lee SH, Kim HR, Cho SM, Kim EK, Nam KH, Chung KS, Kim JY, Kim SY, Kim SK, Kim SY, Lee DS, Kim JM, Park YH, Kim SU. Chae U, et al. Among authors: song is. Mol Ther. 2025 Sep 3;33(9):4394-4413. doi: 10.1016/j.ymthe.2025.06.017. Epub 2025 Jun 14. Mol Ther. 2025. PMID: 40518667 Free article.
2,612 results